Abbott (ABT) and Novo Nordisk (NVO) announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system. The partnership reflects both companies commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring and connected insulin pens.
https://thefly.com/landingPageNews.php?id=2866959
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.